Dimethylcurcumin (ASC‐J9) is a curcumin analogue capable of inhibiting prostate cancer cell proliferation. The mechanism is associated with the unique role of ASC‐J9 in enhancing androgen receptor (AR) degradation. So far, ASC‐J9 has been investigated in typical AR‐associated diseases such as prostate cancer, benign prostatic hypertrophy, bladder cancer, renal diseases, liver diseases, cardiovascular diseases, cutaneous wound, spinal and bulbar muscular atrophy, ovarian cancer and melanoma, exhibiting great potentials in disease control. In this review, the effects and molecular mechanisms of ASC‐J9 on various AR‐associated diseases are summarized. Importantly, the effects of ASC‐J9 and AR antagonists enzalutamide/bicalutamide on prostate cancer are compared in detail and crucial differences are highlighted. At last, the pharmacological effects of ASC‐J9 are summarized and the future applications of ASC‐J9 in AR‐associated disease control are discussed.

中文翻译：

---

二甲基姜黄素（ASC-J9）对雄激素受体相关疾病的作用及分子机制综述

二甲基姜黄素 (ASC-J9) 是一种能够抑制前列腺癌细胞增殖的姜黄素类似物。该机制与 ASC-J9 在增强雄激素受体 (AR) 降解方面的独特作用有关。目前，ASC-J9已在典型的AR相关疾病中进行了研究，如前列腺癌、良性前列腺肥大、膀胱癌、肾脏疾病、肝脏疾病、心血管疾病、皮肤伤口、脊髓和延髓肌肉萎缩、卵巢癌和黑色素瘤，在疾病控制方面表现出巨大的潜力。在这篇综述中，总结了 ASC-J9 对各种 AR 相关疾病的影响和分子机制。重要的是，详细比较了 ASC-J9 和 AR 拮抗剂恩杂鲁胺/比卡鲁胺对前列腺癌的影响，并突出了关键差异。最后，